IL297988A - Antibodies against sars-cov-2 - Google Patents

Info

Publication number

IL297988A

IL297988A IL297988A IL29798822A IL297988A IL 297988 A IL297988 A IL 297988A IL 297988 A IL297988 A IL 297988A IL 29798822 A IL29798822 A IL 29798822A IL 297988 A IL297988 A IL 297988A

Authority

IL

Israel

Prior art keywords

seq

amino acid

antibody

antigen

less

Prior art date

2020-05-08

Links

• Espacenet
• Global Dossier
• Discuss

• 230000027455 binding Effects 0.000 claims description 660
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 527
• 239000012634 fragment Substances 0.000 claims description 466
• 239000000427 antigen Substances 0.000 claims description 465
• 108091007433 antigens Proteins 0.000 claims description 465
• 102000036639 antigens Human genes 0.000 claims description 465
• 210000004027 cell Anatomy 0.000 claims description 334
• 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims description 160
• 208000015181 infectious disease Diseases 0.000 claims description 149
• 238000006467 substitution reaction Methods 0.000 claims description 105
• 239000000203 mixture Substances 0.000 claims description 104
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 98
• 238000000034 method Methods 0.000 claims description 85
• 230000035772 mutation Effects 0.000 claims description 85
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 84
• 239000013598 vector Substances 0.000 claims description 82
• 229920001184 polypeptide Polymers 0.000 claims description 81
• 102000040430 polynucleotide Human genes 0.000 claims description 78
• 108091033319 polynucleotide Proteins 0.000 claims description 78
• 239000002157 polynucleotide Substances 0.000 claims description 77
• 150000001413 amino acids Chemical class 0.000 claims description 69
• 108090000623 proteins and genes Proteins 0.000 claims description 68
• 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 claims description 59
• 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 claims description 57
• 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 claims description 57
• 102000012750 Membrane Glycoproteins Human genes 0.000 claims description 53
• 108010090054 Membrane Glycoproteins Proteins 0.000 claims description 53
• 238000006386 neutralization reaction Methods 0.000 claims description 53
• 230000003472 neutralizing effect Effects 0.000 claims description 51
• 102000004169 proteins and genes Human genes 0.000 claims description 46
• 208000025721 COVID-19 Diseases 0.000 claims description 45
• 208000037847 SARS-CoV-2-infection Diseases 0.000 claims description 42
• 108010037897 DC-specific ICAM-3 grabbing nonintegrin Proteins 0.000 claims description 37
• 210000002845 virion Anatomy 0.000 claims description 35
• 102100040843 C-type lectin domain family 4 member M Human genes 0.000 claims description 32
• 241001678559 COVID-19 virus Species 0.000 claims description 32
• 101000749311 Homo sapiens C-type lectin domain family 4 member M Proteins 0.000 claims description 32
• 241000315672 SARS coronavirus Species 0.000 claims description 30
• 238000002965 ELISA Methods 0.000 claims description 26
• 102100032855 Sialoadhesin Human genes 0.000 claims description 26
• 230000014509 gene expression Effects 0.000 claims description 25
• 108020003175 receptors Proteins 0.000 claims description 25
• 241001112090 Pseudovirus Species 0.000 claims description 24
• 102000005962 receptors Human genes 0.000 claims description 24
• 102000053602 DNA Human genes 0.000 claims description 21
• 108020004414 DNA Proteins 0.000 claims description 21
• 230000003993 interaction Effects 0.000 claims description 19
• 150000002632 lipids Chemical class 0.000 claims description 18
• 102000000844 Cell Surface Receptors Human genes 0.000 claims description 16
• 108010001857 Cell Surface Receptors Proteins 0.000 claims description 16
• 229920002477 rna polymer Polymers 0.000 claims description 16
• 101000868472 Homo sapiens Sialoadhesin Proteins 0.000 claims description 15
• 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 14
• 108091005634 SARS-CoV-2 receptor-binding domains Proteins 0.000 claims description 14
• 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims description 13
• 108010029176 Sialic Acid Binding Ig-like Lectin 1 Proteins 0.000 claims description 13
• 108020004999 messenger RNA Proteins 0.000 claims description 13
• 101000929928 Homo sapiens Angiotensin-converting enzyme 2 Proteins 0.000 claims description 12
• 239000005089 Luciferase Substances 0.000 claims description 12
• 239000002253 acid Substances 0.000 claims description 12
• 210000003719 b-lymphocyte Anatomy 0.000 claims description 12
• 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 12
• 102000048657 human ACE2 Human genes 0.000 claims description 12
• 238000001727 in vivo Methods 0.000 claims description 12
• 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 11
• 108060001084 Luciferase Proteins 0.000 claims description 11
• 238000000684 flow cytometry Methods 0.000 claims description 11
• 238000011282 treatment Methods 0.000 claims description 11
• 230000004913 activation Effects 0.000 claims description 9
• 238000010494 dissociation reaction Methods 0.000 claims description 9
• 230000005593 dissociations Effects 0.000 claims description 9
• 238000010874 in vitro model Methods 0.000 claims description 9
• 208000001528 Coronaviridae Infections Diseases 0.000 claims description 8
• 238000010171 animal model Methods 0.000 claims description 8
• 230000002401 inhibitory effect Effects 0.000 claims description 8
• 125000003729 nucleotide group Chemical group 0.000 claims description 8
• 238000003118 sandwich ELISA Methods 0.000 claims description 8
• 230000000903 blocking effect Effects 0.000 claims description 7
• 230000013595 glycosylation Effects 0.000 claims description 7
• 238000006206 glycosylation reaction Methods 0.000 claims description 7
• 239000002773 nucleotide Substances 0.000 claims description 7
• 239000000725 suspension Substances 0.000 claims description 7
• 108700028369 Alleles Proteins 0.000 claims description 6
• 239000003814 drug Substances 0.000 claims description 6
• 239000002502 liposome Substances 0.000 claims description 6
• 102220599406 Spindlin-1_N501Y_mutation Human genes 0.000 claims description 5
• 238000012575 bio-layer interferometry Methods 0.000 claims description 5
• 239000003085 diluting agent Substances 0.000 claims description 5
• 239000002105 nanoparticle Substances 0.000 claims description 5
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 5
• 238000003745 diagnosis Methods 0.000 claims description 4
• 238000002360 preparation method Methods 0.000 claims description 4
• 239000003981 vehicle Substances 0.000 claims description 4
• 108010047827 Sialic Acid Binding Immunoglobulin-like Lectins Proteins 0.000 claims description 3
• 102000007073 Sialic Acid Binding Immunoglobulin-like Lectins Human genes 0.000 claims description 3
• 102220599422 Spindlin-1_L452R_mutation Human genes 0.000 claims description 3
• 230000003213 activating effect Effects 0.000 claims description 3
• 210000004369 blood Anatomy 0.000 claims description 3
• 239000008280 blood Substances 0.000 claims description 3
• 238000000338 in vitro Methods 0.000 claims description 3
• 102000029749 Microtubule Human genes 0.000 claims description 2
• 108091022875 Microtubule Proteins 0.000 claims description 2
• 102220599656 Spindlin-1_E484K_mutation Human genes 0.000 claims description 2
• 102220590604 Spindlin-1_K417N_mutation Human genes 0.000 claims description 2
• 102220599420 Spindlin-1_N501T_mutation Human genes 0.000 claims description 2
• 102220599655 Spindlin-1_S477N_mutation Human genes 0.000 claims description 2
• 102220599660 Spindlin-1_T478K_mutation Human genes 0.000 claims description 2
• 102220599416 Spindlin-1_Y453F_mutation Human genes 0.000 claims description 2
• 238000013459 approach Methods 0.000 claims description 2
• 239000003937 drug carrier Substances 0.000 claims description 2
• 102000056960 human SIGLEC1 Human genes 0.000 claims description 2
• 239000002960 lipid emulsion Substances 0.000 claims description 2
• 239000000693 micelle Substances 0.000 claims description 2
• 210000004688 microtubule Anatomy 0.000 claims description 2
• 239000013639 protein trimer Substances 0.000 claims description 2
• 239000002047 solid lipid nanoparticle Substances 0.000 claims description 2
• 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 claims 1
• 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 claims 1
• 235000001014 amino acid Nutrition 0.000 description 75
• 150000007523 nucleic acids Chemical class 0.000 description 71
• 102000039446 nucleic acids Human genes 0.000 description 69
• 108020004707 nucleic acids Proteins 0.000 description 69
• 229940024606 amino acid Drugs 0.000 description 57
• 235000018102 proteins Nutrition 0.000 description 41
• 229940096437 Protein S Drugs 0.000 description 32
• 101710198474 Spike protein Proteins 0.000 description 32
• 241000700605 Viruses Species 0.000 description 32
• 238000003556 assay Methods 0.000 description 27
• -1 y-carboxyglutamate Chemical compound 0.000 description 23
• 101000674040 Homo sapiens Serine-tRNA ligase, mitochondrial Proteins 0.000 description 21
• 102100040597 Serine-tRNA ligase, mitochondrial Human genes 0.000 description 21
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
• 230000000694 effects Effects 0.000 description 20
• 230000006870 function Effects 0.000 description 20
• 241000714177 Murine leukemia virus Species 0.000 description 18
• 230000004048 modification Effects 0.000 description 18
• 238000012986 modification Methods 0.000 description 18
• 239000013612 plasmid Substances 0.000 description 18
• 102100024952 Protein CBFA2T1 Human genes 0.000 description 17
• 150000001875 compounds Chemical class 0.000 description 17
• 201000010099 disease Diseases 0.000 description 17
• 239000013603 viral vector Substances 0.000 description 14
• 239000007788 liquid Substances 0.000 description 13
• 238000011002 quantification Methods 0.000 description 13
• 230000003612 virological effect Effects 0.000 description 13
• 102100038276 Protein Red Human genes 0.000 description 12
• 210000004899 c-terminal region Anatomy 0.000 description 12
• 230000000875 corresponding effect Effects 0.000 description 12
• 210000004072 lung Anatomy 0.000 description 12
• 108010087819 Fc receptors Proteins 0.000 description 11
• 102000009109 Fc receptors Human genes 0.000 description 11
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 11
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 11
• 230000001404 mediated effect Effects 0.000 description 11
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 10
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 10
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 10
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
• 241000711975 Vesicular stomatitis virus Species 0.000 description 10
• 238000004458 analytical method Methods 0.000 description 10
• 230000005764 inhibitory process Effects 0.000 description 10
• 239000004480 active ingredient Substances 0.000 description 9
• 230000008901 benefit Effects 0.000 description 9
• 238000002474 experimental method Methods 0.000 description 9
• 230000000069 prophylactic effect Effects 0.000 description 9
• 208000024891 symptom Diseases 0.000 description 9
• 230000001225 therapeutic effect Effects 0.000 description 9
• 238000001890 transfection Methods 0.000 description 9
• 241001465754 Metazoa Species 0.000 description 8
• 125000000539 amino acid group Chemical group 0.000 description 8
• 229940121363 anti-inflammatory agent Drugs 0.000 description 8
• 239000002260 anti-inflammatory agent Substances 0.000 description 8
• 239000012636 effector Substances 0.000 description 8
• 239000000463 material Substances 0.000 description 8
• 239000008194 pharmaceutical composition Substances 0.000 description 8
• 230000002829 reductive effect Effects 0.000 description 8
• 239000000523 sample Substances 0.000 description 8
• 239000004472 Lysine Substances 0.000 description 7
• 108020000999 Viral RNA Proteins 0.000 description 7
• 239000000443 aerosol Substances 0.000 description 7
• 239000003795 chemical substances by application Substances 0.000 description 7
• 238000002648 combination therapy Methods 0.000 description 7
• 238000009472 formulation Methods 0.000 description 7
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 7
• 241000894007 species Species 0.000 description 7
• 108091026890 Coding region Proteins 0.000 description 6
• 241000711573 Coronaviridae Species 0.000 description 6
• 241000699800 Cricetinae Species 0.000 description 6
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
• 108091028043 Nucleic acid sequence Proteins 0.000 description 6
• 108090001074 Nucleocapsid Proteins Proteins 0.000 description 6
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 6
• 239000003443 antiviral agent Substances 0.000 description 6
• 238000001514 detection method Methods 0.000 description 6
• 230000036541 health Effects 0.000 description 6
• 210000004185 liver Anatomy 0.000 description 6
• 210000002540 macrophage Anatomy 0.000 description 6
• 210000004962 mammalian cell Anatomy 0.000 description 6
• 210000001616 monocyte Anatomy 0.000 description 6
• 229920000642 polymer Polymers 0.000 description 6
• 230000004481 post-translational protein modification Effects 0.000 description 6
• 239000007787 solid Substances 0.000 description 6
• 239000000243 solution Substances 0.000 description 6
• 239000000126 substance Substances 0.000 description 6
• 108060003951 Immunoglobulin Proteins 0.000 description 5
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
• 241000699673 Mesocricetus auratus Species 0.000 description 5
• 241000699666 Mus <mouse, genus> Species 0.000 description 5
• 239000013543 active substance Substances 0.000 description 5
• 238000012217 deletion Methods 0.000 description 5
• 230000037430 deletion Effects 0.000 description 5
• 238000004520 electroporation Methods 0.000 description 5
• 230000004927 fusion Effects 0.000 description 5
• 230000002068 genetic effect Effects 0.000 description 5
• 102000018358 immunoglobulin Human genes 0.000 description 5
• 238000012744 immunostaining Methods 0.000 description 5
• 210000003292 kidney cell Anatomy 0.000 description 5
• 238000004519 manufacturing process Methods 0.000 description 5
• 229920001223 polyethylene glycol Polymers 0.000 description 5
• 230000003449 preventive effect Effects 0.000 description 5
• 230000009467 reduction Effects 0.000 description 5
• 230000004083 survival effect Effects 0.000 description 5
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
• 102000014914 Carrier Proteins Human genes 0.000 description 4
• 102100031673 Corneodesmosin Human genes 0.000 description 4
• 101710139375 Corneodesmosin Proteins 0.000 description 4
• 241000196324 Embryophyta Species 0.000 description 4
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
• 241000238631 Hexapoda Species 0.000 description 4
• 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 description 4
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
• 206010057249 Phagocytosis Diseases 0.000 description 4
• 102100031989 Transmembrane protease serine 2 Human genes 0.000 description 4
• 125000001931 aliphatic group Chemical group 0.000 description 4
• 108091008324 binding proteins Proteins 0.000 description 4
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
• 230000000295 complement effect Effects 0.000 description 4
• 208000035475 disorder Diseases 0.000 description 4
• 210000003979 eosinophil Anatomy 0.000 description 4
• 210000003527 eukaryotic cell Anatomy 0.000 description 4
• 239000013604 expression vector Substances 0.000 description 4
• 230000016784 immunoglobulin production Effects 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• 238000007918 intramuscular administration Methods 0.000 description 4
• 210000005229 liver cell Anatomy 0.000 description 4
• 239000002609 medium Substances 0.000 description 4
• 239000002245 particle Substances 0.000 description 4
• 230000008782 phagocytosis Effects 0.000 description 4
• 239000013600 plasmid vector Substances 0.000 description 4
• 230000008569 process Effects 0.000 description 4
• 210000001236 prokaryotic cell Anatomy 0.000 description 4
• 238000000746 purification Methods 0.000 description 4
• 239000011780 sodium chloride Substances 0.000 description 4
• 239000006228 supernatant Substances 0.000 description 4
• 238000002560 therapeutic procedure Methods 0.000 description 4
• 210000001519 tissue Anatomy 0.000 description 4
• 238000013518 transcription Methods 0.000 description 4
• 230000035897 transcription Effects 0.000 description 4
• 238000013519 translation Methods 0.000 description 4
• 241001430294 unidentified retrovirus Species 0.000 description 4
• 229960005486 vaccine Drugs 0.000 description 4
• 206010069754 Acquired gene mutation Diseases 0.000 description 3
• 108091008875 B cell receptors Proteins 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• 241000282693 Cercopithecidae Species 0.000 description 3
• 108020004705 Codon Proteins 0.000 description 3
• 241001663880 Gammaretrovirus Species 0.000 description 3
• 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 3
• 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 3
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
• 241000713666 Lentivirus Species 0.000 description 3
• 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 description 3
• 241000124008 Mammalia Species 0.000 description 3
• 206010028980 Neoplasm Diseases 0.000 description 3
• 239000002202 Polyethylene glycol Substances 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 3
• 101001024637 Severe acute respiratory syndrome coronavirus 2 Nucleoprotein Proteins 0.000 description 3
• 241000700584 Simplexvirus Species 0.000 description 3
• 210000001744 T-lymphocyte Anatomy 0.000 description 3
• 108700019146 Transgenes Proteins 0.000 description 3
• 230000000890 antigenic effect Effects 0.000 description 3
• 230000000712 assembly Effects 0.000 description 3
• 238000000429 assembly Methods 0.000 description 3
• 230000001580 bacterial effect Effects 0.000 description 3
• 230000004071 biological effect Effects 0.000 description 3
• 230000015572 biosynthetic process Effects 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• 201000011510 cancer Diseases 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 239000000969 carrier Substances 0.000 description 3
• 230000007910 cell fusion Effects 0.000 description 3
• 239000011248 coating agent Substances 0.000 description 3
• 238000000576 coating method Methods 0.000 description 3
• 238000004132 cross linking Methods 0.000 description 3
• 235000018417 cysteine Nutrition 0.000 description 3
• 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• 238000010790 dilution Methods 0.000 description 3
• 239000012895 dilution Substances 0.000 description 3
• 239000000975 dye Substances 0.000 description 3
• 210000003038 endothelium Anatomy 0.000 description 3
• 238000005516 engineering process Methods 0.000 description 3
• 108020001507 fusion proteins Proteins 0.000 description 3
• 102000037865 fusion proteins Human genes 0.000 description 3
• 210000004408 hybridoma Anatomy 0.000 description 3
• 230000028993 immune response Effects 0.000 description 3
• 238000010166 immunofluorescence Methods 0.000 description 3
• 230000002163 immunogen Effects 0.000 description 3
• 230000005847 immunogenicity Effects 0.000 description 3
• 238000010348 incorporation Methods 0.000 description 3
• 238000011534 incubation Methods 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• 239000011159 matrix material Substances 0.000 description 3
• 210000000440 neutrophil Anatomy 0.000 description 3
• 210000004940 nucleus Anatomy 0.000 description 3
• 238000004806 packaging method and process Methods 0.000 description 3
• 244000052769 pathogen Species 0.000 description 3
• 230000001124 posttranscriptional effect Effects 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 230000001681 protective effect Effects 0.000 description 3
• 230000001105 regulatory effect Effects 0.000 description 3
• 230000003362 replicative effect Effects 0.000 description 3
• 230000004044 response Effects 0.000 description 3
• 238000012552 review Methods 0.000 description 3
• 210000002966 serum Anatomy 0.000 description 3
• 230000037439 somatic mutation Effects 0.000 description 3
• 239000003381 stabilizer Substances 0.000 description 3
• 239000004094 surface-active agent Substances 0.000 description 3
• 239000003826 tablet Substances 0.000 description 3
• 230000008685 targeting Effects 0.000 description 3
• 238000012360 testing method Methods 0.000 description 3
• 230000009466 transformation Effects 0.000 description 3
• 241000701161 unidentified adenovirus Species 0.000 description 3
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
• IPJDHSYCSQAODE-UHFFFAOYSA-N 5-chloromethylfluorescein diacetate Chemical compound O1C(=O)C2=CC(CCl)=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 IPJDHSYCSQAODE-UHFFFAOYSA-N 0.000 description 2
• LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
• LXEKPEMOWBOYRF-QDBORUFSSA-N AAPH Chemical compound Cl.Cl.NC(=N)C(C)(C)\N=N\C(C)(C)C(N)=N LXEKPEMOWBOYRF-QDBORUFSSA-N 0.000 description 2
• 102220579649 ATP-dependent RNA helicase A_K417N_mutation Human genes 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
• 241000894006 Bacteria Species 0.000 description 2
• 241000008904 Betacoronavirus Species 0.000 description 2
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
• 241000283707 Capra Species 0.000 description 2
• 241000702421 Dependoparvovirus Species 0.000 description 2
• 229920002307 Dextran Polymers 0.000 description 2
• 206010061818 Disease progression Diseases 0.000 description 2
• 102000004190 Enzymes Human genes 0.000 description 2
• 108090000790 Enzymes Proteins 0.000 description 2
• 241000588724 Escherichia coli Species 0.000 description 2
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
• 241000233866 Fungi Species 0.000 description 2
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
• 208000031886 HIV Infections Diseases 0.000 description 2
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
• 241000725303 Human immunodeficiency virus Species 0.000 description 2
• 102100034343 Integrase Human genes 0.000 description 2
• 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
• 108091092195 Intron Proteins 0.000 description 2
• 208000011200 Kawasaki disease Diseases 0.000 description 2
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
• LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical group CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
• 239000004166 Lanolin Substances 0.000 description 2
• 102220490323 Matrix metalloproteinase-27_N55Q_mutation Human genes 0.000 description 2
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
• 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 2
• 102000011931 Nucleoproteins Human genes 0.000 description 2
• 108010061100 Nucleoproteins Proteins 0.000 description 2
• 240000007019 Oxalis corniculata Species 0.000 description 2
• 101100237801 Phaeosphaeria nodorum (strain SN15 / ATCC MYA-4574 / FGSC 10173) MLNS gene Proteins 0.000 description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 description 2
• 241000288906 Primates Species 0.000 description 2
• 206010036790 Productive cough Diseases 0.000 description 2
• 102100039641 Protein MFI Human genes 0.000 description 2
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
• 241000700159 Rattus Species 0.000 description 2
• 241000712907 Retroviridae Species 0.000 description 2
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
• 241000008910 Severe acute respiratory syndrome-related coronavirus Species 0.000 description 2
• 108020004459 Small interfering RNA Proteins 0.000 description 2
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
• 238000011053 TCID50 method Methods 0.000 description 2
• ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 238000007792 addition Methods 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 235000004279 alanine Nutrition 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• 210000004102 animal cell Anatomy 0.000 description 2
• 125000003118 aryl group Chemical group 0.000 description 2
• 208000006673 asthma Diseases 0.000 description 2
• 239000012472 biological sample Substances 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 description 2
• 235000011010 calcium phosphates Nutrition 0.000 description 2
• 239000005018 casein Substances 0.000 description 2
• BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
• 235000021240 caseins Nutrition 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 235000012000 cholesterol Nutrition 0.000 description 2
• 230000002759 chromosomal effect Effects 0.000 description 2
• 210000000349 chromosome Anatomy 0.000 description 2
• 238000003776 cleavage reaction Methods 0.000 description 2
• 239000003086 colorant Substances 0.000 description 2
• 230000000052 comparative effect Effects 0.000 description 2
• 230000009089 cytolysis Effects 0.000 description 2
• 210000000805 cytoplasm Anatomy 0.000 description 2
• OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• 231100000517 death Toxicity 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 210000004443 dendritic cell Anatomy 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 239000000539 dimer Substances 0.000 description 2
• 241001493065 dsRNA viruses Species 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 229940088598 enzyme Drugs 0.000 description 2
• 210000003743 erythrocyte Anatomy 0.000 description 2
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 235000003599 food sweetener Nutrition 0.000 description 2
• 239000007789 gas Substances 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 239000007903 gelatin capsule Substances 0.000 description 2
• 230000004077 genetic alteration Effects 0.000 description 2
• 231100000118 genetic alteration Toxicity 0.000 description 2
• 210000004602 germ cell Anatomy 0.000 description 2
• UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
• 210000003630 histaminocyte Anatomy 0.000 description 2
• 210000005260 human cell Anatomy 0.000 description 2
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 230000036039 immunity Effects 0.000 description 2
• 238000003365 immunocytochemistry Methods 0.000 description 2
• 238000003364 immunohistochemistry Methods 0.000 description 2
• 238000001114 immunoprecipitation Methods 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 230000002147 killing effect Effects 0.000 description 2
• 229940039717 lanolin Drugs 0.000 description 2
• 235000019388 lanolin Nutrition 0.000 description 2
• 238000011031 large-scale manufacturing process Methods 0.000 description 2
• 210000005265 lung cell Anatomy 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 229930182817 methionine Chemical group 0.000 description 2
• OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
• 244000005700 microbiome Species 0.000 description 2
• 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 2
• 201000000050 myeloid neoplasm Diseases 0.000 description 2
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 238000005457 optimization Methods 0.000 description 2
• 230000003647 oxidation Effects 0.000 description 2
• 238000007254 oxidation reaction Methods 0.000 description 2
• 230000001717 pathogenic effect Effects 0.000 description 2
• 239000002504 physiological saline solution Substances 0.000 description 2
• 229940068917 polyethylene glycols Drugs 0.000 description 2
• 238000001556 precipitation Methods 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 230000002035 prolonged effect Effects 0.000 description 2
• 230000004952 protein activity Effects 0.000 description 2
• 230000012846 protein folding Effects 0.000 description 2
• 230000010076 replication Effects 0.000 description 2
• 230000000241 respiratory effect Effects 0.000 description 2
• 230000001177 retroviral effect Effects 0.000 description 2
• 238000010839 reverse transcription Methods 0.000 description 2
• 102200056390 rs12204826 Human genes 0.000 description 2
• 102200128238 rs201124247 Human genes 0.000 description 2
• 230000007017 scission Effects 0.000 description 2
• 238000013207 serial dilution Methods 0.000 description 2
• 239000001509 sodium citrate Substances 0.000 description 2
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
• 239000008247 solid mixture Substances 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 210000004988 splenocyte Anatomy 0.000 description 2
• 208000024794 sputum Diseases 0.000 description 2
• 210000003802 sputum Anatomy 0.000 description 2
• 230000006641 stabilisation Effects 0.000 description 2
• 238000011105 stabilization Methods 0.000 description 2
• 238000010186 staining Methods 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 125000001424 substituent group Chemical group 0.000 description 2
• 239000011593 sulfur Substances 0.000 description 2
• 229910052717 sulfur Inorganic materials 0.000 description 2
• 239000003765 sweetening agent Substances 0.000 description 2
• RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
• 238000011200 topical administration Methods 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• 230000009261 transgenic effect Effects 0.000 description 2
• 238000011269 treatment regimen Methods 0.000 description 2
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
• 238000001262 western blot Methods 0.000 description 2
• 210000005253 yeast cell Anatomy 0.000 description 2
• DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
• HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 description 1
• HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
• UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
• NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
• PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
• CCTFAOUOYLVUFG-UHFFFAOYSA-N 2-(1-amino-1-imino-2-methylpropan-2-yl)azo-2-methylpropanimidamide Chemical compound NC(=N)C(C)(C)N=NC(C)(C)C(N)=N CCTFAOUOYLVUFG-UHFFFAOYSA-N 0.000 description 1
• 108020005345 3' Untranslated Regions Proteins 0.000 description 1
• XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• 229930024421 Adenine Natural products 0.000 description 1
• GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
• IPWKGIFRRBGCJO-IMJSIDKUSA-N Ala-Ser Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O IPWKGIFRRBGCJO-IMJSIDKUSA-N 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• 241000710929 Alphavirus Species 0.000 description 1
• 108091093088 Amplicon Proteins 0.000 description 1
• 241000024188 Andala Species 0.000 description 1
• 108010083359 Antigen Receptors Proteins 0.000 description 1
• 102000006306 Antigen Receptors Human genes 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 230000003844 B-cell-activation Effects 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
• 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 1
• 241000282552 Chlorocebus aethiops Species 0.000 description 1
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
• 108020004638 Circular DNA Proteins 0.000 description 1
• 102220585969 Claspin_S982A_mutation Human genes 0.000 description 1
• 108091033380 Coding strand Proteins 0.000 description 1
• 108091035707 Consensus sequence Proteins 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 206010011224 Cough Diseases 0.000 description 1
• 241000701022 Cytomegalovirus Species 0.000 description 1
• 241000450599 DNA viruses Species 0.000 description 1
• 229920001353 Dextrin Polymers 0.000 description 1
• 239000004375 Dextrin Substances 0.000 description 1
• 206010012735 Diarrhoea Diseases 0.000 description 1
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• 208000000059 Dyspnea Diseases 0.000 description 1
• 206010013975 Dyspnoeas Diseases 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 101100379080 Emericella variicolor andB gene Proteins 0.000 description 1
• 241000713730 Equine infectious anemia virus Species 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• 108700024394 Exon Proteins 0.000 description 1
• 101150021185 FGF gene Proteins 0.000 description 1
• 241000713800 Feline immunodeficiency virus Species 0.000 description 1
• 241000714165 Feline leukemia virus Species 0.000 description 1
• 241000714174 Feline sarcoma virus Species 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 241000710831 Flavivirus Species 0.000 description 1
• 208000000666 Fowlpox Diseases 0.000 description 1
• 102100035233 Furin Human genes 0.000 description 1
• 108090001126 Furin Proteins 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 102000002068 Glycopeptides Human genes 0.000 description 1
• 108010015899 Glycopeptides Proteins 0.000 description 1
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
• 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
• 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 241000941423 Grom virus Species 0.000 description 1
• 208000037357 HIV infectious disease Diseases 0.000 description 1
• 241001272567 Hominoidea Species 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000773743 Homo sapiens Angiotensin-converting enzyme Proteins 0.000 description 1
• 101000840257 Homo sapiens Immunoglobulin kappa constant Proteins 0.000 description 1
• 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
• 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
• 108010003272 Hyaluronate lyase Proteins 0.000 description 1
• 102000001974 Hyaluronidases Human genes 0.000 description 1
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
• 102000026633 IL6 Human genes 0.000 description 1
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
• 102100029572 Immunoglobulin kappa constant Human genes 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
• 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
• 108090001005 Interleukin-6 Proteins 0.000 description 1
• 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
• 108010002586 Interleukin-7 Proteins 0.000 description 1
• 108090001007 Interleukin-8 Proteins 0.000 description 1
• 108010002335 Interleukin-9 Proteins 0.000 description 1
• KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 1
• 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical group OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical group C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
• QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Chemical group CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
• 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
• 125000000773 L-serino group Chemical group [H]OC(=O)[C@@]([H])(N([H])*)C([H])([H])O[H] 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
• 102000004856 Lectins Human genes 0.000 description 1
• 108090001090 Lectins Proteins 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 201000005505 Measles Diseases 0.000 description 1
• 244000246386 Mentha pulegium Species 0.000 description 1
• 235000016257 Mentha pulegium Nutrition 0.000 description 1
• 235000004357 Mentha x piperita Nutrition 0.000 description 1
• 108700011259 MicroRNAs Proteins 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 108020005196 Mitochondrial DNA Proteins 0.000 description 1
• 241000713869 Moloney murine leukemia virus Species 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
• 241000714209 Norwalk virus Species 0.000 description 1
• 241000702244 Orthoreovirus Species 0.000 description 1
• 241000713747 Ovine lentivirus Species 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 241000282579 Pan Species 0.000 description 1
• 229930040373 Paraformaldehyde Natural products 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 241000009328 Perro Species 0.000 description 1
• 239000004264 Petrolatum Substances 0.000 description 1
• 241000709664 Picornaviridae Species 0.000 description 1
• 241000276498 Pollachius virens Species 0.000 description 1
• 229920002873 Polyethylenimine Polymers 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 241000125945 Protoparvovirus Species 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• 238000011529 RT qPCR Methods 0.000 description 1
• 206010037742 Rabies Diseases 0.000 description 1
• 241000711798 Rabies lyssavirus Species 0.000 description 1
• 241000700157 Rattus norvegicus Species 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 241000712909 Reticuloendotheliosis virus Species 0.000 description 1
• NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
• 108091006197 SARS-CoV-2 Nucleocapsid Protein Proteins 0.000 description 1
• 241001678561 Sarbecovirus Species 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• 229920001800 Shellac Polymers 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
• DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
• 102220590324 Spindlin-1_D80A_mutation Human genes 0.000 description 1
• 102220590628 Spindlin-1_L18F_mutation Human genes 0.000 description 1
• 241000256248 Spodoptera Species 0.000 description 1
• 241000256251 Spodoptera frugiperda Species 0.000 description 1
• 241000713675 Spumavirus Species 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 102220510809 Toll-like receptor 3_P681H_mutation Human genes 0.000 description 1
• 101710120037 Toxin CcdB Proteins 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
• 241000255993 Trichoplusia ni Species 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 108091023045 Untranslated Region Proteins 0.000 description 1
• 206010046865 Vaccinia virus infection Diseases 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
• 108020005202 Viral DNA Proteins 0.000 description 1
• 241000713325 Visna/maedi virus Species 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• 229960004150 aciclovir Drugs 0.000 description 1
• MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 229960000643 adenine Drugs 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 229960004238 anakinra Drugs 0.000 description 1
• 238000013103 analytical ultracentrifugation Methods 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000000692 anti-sense effect Effects 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 230000001640 apoptogenic effect Effects 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 125000004429 atom Chemical group 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• 208000004668 avian leukosis Diseases 0.000 description 1
• 235000013871 bee wax Nutrition 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 239000013060 biological fluid Substances 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 239000007853 buffer solution Substances 0.000 description 1
• 238000004422 calculation algorithm Methods 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 229920006317 cationic polymer Polymers 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000005889 cellular cytotoxicity Effects 0.000 description 1
• 230000007969 cellular immunity Effects 0.000 description 1
• 208000019065 cervical carcinoma Diseases 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 238000012412 chemical coupling Methods 0.000 description 1
• 238000006243 chemical reaction Methods 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 229940112822 chewing gum Drugs 0.000 description 1
• 235000015218 chewing gum Nutrition 0.000 description 1
• 150000001860 citric acid derivatives Chemical class 0.000 description 1
• 238000003759 clinical diagnosis Methods 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
• 230000024203 complement activation Effects 0.000 description 1
• 230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
• 239000002299 complementary DNA Substances 0.000 description 1
• 239000007891 compressed tablet Substances 0.000 description 1
• 230000001010 compromised effect Effects 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 235000008504 concentrate Nutrition 0.000 description 1
• 208000028831 congenital heart disease Diseases 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 230000001186 cumulative effect Effects 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 239000000430 cytokine receptor antagonist Substances 0.000 description 1
• 229940104302 cytosine Drugs 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 230000006240 deamidation Effects 0.000 description 1
• 230000007423 decrease Effects 0.000 description 1
• 230000018044 dehydration Effects 0.000 description 1
• 238000006297 dehydration reaction Methods 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
• 235000019425 dextrin Nutrition 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 238000002050 diffraction method Methods 0.000 description 1
• 238000007865 diluting Methods 0.000 description 1
• 238000000375 direct analysis in real time Methods 0.000 description 1
• 230000006806 disease prevention Effects 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• 239000012153 distilled water Substances 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 150000002019 disulfides Chemical class 0.000 description 1
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 229940079593 drug Drugs 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 208000017574 dry cough Diseases 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 238000012063 dual-affinity re-targeting Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 239000002702 enteric coating Substances 0.000 description 1
• 238000009505 enteric coating Methods 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 238000010195 expression analysis Methods 0.000 description 1
• 239000013613 expression plasmid Substances 0.000 description 1
• ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 description 1
• 229950008454 favipiravir Drugs 0.000 description 1
• 239000012091 fetal bovine serum Substances 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 235000019264 food flavour enhancer Nutrition 0.000 description 1
• 230000033581 fucosylation Effects 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 238000001476 gene delivery Methods 0.000 description 1
• 238000012239 gene modification Methods 0.000 description 1
• 238000001415 gene therapy Methods 0.000 description 1
• 238000010353 genetic engineering Methods 0.000 description 1
• 230000005017 genetic modification Effects 0.000 description 1
• 235000013617 genetically modified food Nutrition 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 235000011187 glycerol Nutrition 0.000 description 1
• 125000003712 glycosamine group Chemical group 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 238000011553 hamster model Methods 0.000 description 1
• 201000005787 hematologic cancer Diseases 0.000 description 1
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• 231100000283 hepatitis Toxicity 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 239000012456 homogeneous solution Substances 0.000 description 1
• 235000001050 hortel pimenta Nutrition 0.000 description 1
• 102000056252 human ACE Human genes 0.000 description 1
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
• 229960002773 hyaluronidase Drugs 0.000 description 1
• 238000009396 hybridization Methods 0.000 description 1
• 150000002431 hydrogen Chemical group 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 229960002591 hydroxyproline Drugs 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 230000032226 immune complex clearance Effects 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 230000003832 immune regulation Effects 0.000 description 1
• 229940127121 immunoconjugate Drugs 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 108091008042 inhibitory receptors Proteins 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 230000002601 intratumoral effect Effects 0.000 description 1
• 239000003456 ion exchange resin Substances 0.000 description 1
• 229920003303 ion-exchange polymer Polymers 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• 238000006317 isomerization reaction Methods 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• 238000005304 joining Methods 0.000 description 1
• 230000000366 juvenile effect Effects 0.000 description 1
• 210000001865 kupffer cell Anatomy 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 239000002523 lectin Substances 0.000 description 1
• 229940121292 leronlimab Drugs 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 238000001638 lipofection Methods 0.000 description 1
• 208000019423 liver disease Diseases 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 238000011551 log transformation method Methods 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 229960004525 lopinavir Drugs 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 238000004020 luminiscence type Methods 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 238000007726 management method Methods 0.000 description 1
• 238000013507 mapping Methods 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
• 229940012189 methyl orange Drugs 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 229960001047 methyl salicylate Drugs 0.000 description 1
• 229960002216 methylparaben Drugs 0.000 description 1
• LSDPWZHWYPCBBB-UHFFFAOYSA-O methylsulfide anion Chemical compound [SH2+]C LSDPWZHWYPCBBB-UHFFFAOYSA-O 0.000 description 1
• 239000002679 microRNA Substances 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 238000001000 micrograph Methods 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 239000008267 milk Substances 0.000 description 1
• 210000004080 milk Anatomy 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 108091005601 modified peptides Proteins 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 210000000822 natural killer cell Anatomy 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 230000010807 negative regulation of binding Effects 0.000 description 1
• 108010068617 neonatal Fc receptor Proteins 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 231100000344 non-irritating Toxicity 0.000 description 1
• 239000000346 nonvolatile oil Substances 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 150000003833 nucleoside derivatives Chemical class 0.000 description 1
• 230000000474 nursing effect Effects 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 239000008203 oral pharmaceutical composition Substances 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 229920002866 paraformaldehyde Polymers 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 230000008823 permeabilization Effects 0.000 description 1
• 229940066842 petrolatum Drugs 0.000 description 1
• 235000019271 petrolatum Nutrition 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• 235000021317 phosphate Nutrition 0.000 description 1
• WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 230000001817 pituitary effect Effects 0.000 description 1
• 229940068196 placebo Drugs 0.000 description 1
• 239000000902 placebo Substances 0.000 description 1
• 210000002826 placenta Anatomy 0.000 description 1
• 210000004180 plasmocyte Anatomy 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 210000002706 plastid Anatomy 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 150000004804 polysaccharides Chemical class 0.000 description 1
• 230000006555 post-translational control Effects 0.000 description 1
• 229960004618 prednisone Drugs 0.000 description 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 229940002612 prodrug Drugs 0.000 description 1
• 239000000651 prodrug Substances 0.000 description 1
• 239000000047 product Substances 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 108020001580 protein domains Proteins 0.000 description 1
• 230000005180 public health Effects 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 210000000664 rectum Anatomy 0.000 description 1
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
• RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 description 1
• RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
• 231100000205 reproductive and developmental toxicity Toxicity 0.000 description 1
• 238000004007 reversed phase HPLC Methods 0.000 description 1
• NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
• 229960000311 ritonavir Drugs 0.000 description 1
• 102220053106 rs199537178 Human genes 0.000 description 1
• 102220075059 rs529697285 Human genes 0.000 description 1
• 102220046286 rs587782805 Human genes 0.000 description 1
• 102220033185 rs62646881 Human genes 0.000 description 1
• HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
• 229960000215 ruxolitinib Drugs 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 229940081974 saccharin Drugs 0.000 description 1
• 235000019204 saccharin Nutrition 0.000 description 1
• 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
• 210000003079 salivary gland Anatomy 0.000 description 1
• 150000003839 salts Chemical class 0.000 description 1
• 235000014102 seafood Nutrition 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 210000002955 secretory cell Anatomy 0.000 description 1
• 238000002864 sequence alignment Methods 0.000 description 1
• 210000000717 sertoli cell Anatomy 0.000 description 1
• 239000004208 shellac Substances 0.000 description 1
• 229940113147 shellac Drugs 0.000 description 1
• 235000013874 shellac Nutrition 0.000 description 1
• ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
• 229960003323 siltuximab Drugs 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
• 229960002063 sofosbuvir Drugs 0.000 description 1
• TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 description 1
• 238000001179 sorption measurement Methods 0.000 description 1
• 238000004611 spectroscopical analysis Methods 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• 210000000115 thoracic cavity Anatomy 0.000 description 1
• 229940113082 thymine Drugs 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 229960003989 tocilizumab Drugs 0.000 description 1
• 238000002627 tracheal intubation Methods 0.000 description 1
• FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
• 230000005026 transcription initiation Effects 0.000 description 1
• 230000002463 transducing effect Effects 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 238000003146 transient transfection Methods 0.000 description 1
• 230000014616 translation Effects 0.000 description 1
• 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 239000008243 triphasic system Substances 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 241000712461 unidentified influenza virus Species 0.000 description 1
• 229940035893 uracil Drugs 0.000 description 1
• 208000007089 vaccinia Diseases 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 239000008215 water for injection Substances 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 229940075420 xanthine Drugs 0.000 description 1
• 229960002555 zidovudine Drugs 0.000 description 1
• HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1